Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03316300 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
A Phase 3 study of Macular Telangiectasia Type 2 (MacTel), sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT03316300: Completed Phase 3 study of Macular Telangiectasia Type 2 (MacTel), sponsored by Neurotech Pharmaceuticals.
NCT03316300 is a Phase 3 study of Macular Telangiectasia Type 2 (MacTel) that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 120 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03316300, a Phase 3 study of Macular Telangiectasia Type 2 (MacTel), has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
Primary Outcome
The rate of change in the area of EZ loss (IS/OS; macular photoreceptor loss) from baseline through month 24, as assessed using SD-OCT in the study eye of subjects with MacTel.
Conditions Studied
Interventions
- PROCEDURE Sham Procedure
- COMBINATION_PRODUCT NT-501
Study Locations (20)
California
- Scripps Clinic Medical Group - La Jolla
- Jules Stein Eye Institute / David Geffen School of Medicine - Los Angeles
- Byers Eye Institute at Stanford University - Palo Alto
- Bay Area Retina Associates - Walnut Creek
Maryland
- National Institute of Health, NIH - Bethesda
- Cumberland Valley Retina Consultants - Hagerstown
Other
- Lariboisiere Hospital - Paris
- Moorfields Eye Hospital NHS Foundation Trust - London
Colorado
- Retina Consultants of Southern Colorado, P.C. - Colorado Springs
Louisiana
- Retina Associates of New Orleans - Metairie
Michigan
- Associated Retinal Consultants, P.C. - Royal Oak
Nevada
- Sierra Eye Associates - Reno
Ohio
- Retina Associates of Cleveland, Inc. - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-11-24 |
| Est. Completion | 2022-09-23 |
| Phase | Phase 3 |
What the finished NCT03316300 record still lists
NCT03316300 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Macular Telangiectasia Type 2 (MacTel) appearing as the primary indexed condition, and to 2 interventions - of which Sham Procedure is the first listed.
NCT03316300 names 20 study sites across 15 states, led by California, Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT03316300 about?
NCT03316300 is a clinical study titled "A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A". This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
What is the current status of trial NCT03316300?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2017-11-24. Estimated completion is 2022-09-23.
What conditions does trial NCT03316300 study?
This clinical trial studies the following conditions: Macular Telangiectasia Type 2 (MacTel).
What interventions are being tested in trial NCT03316300?
The interventions under investigation include: Sham Procedure (PROCEDURE), NT-501 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03316300?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03316300 being conducted?
This trial has 20 study locations across California, Colorado, Louisiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03316300's enrollment target sits among peer trials
120 1619th of 2000 higher than 361 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI